Gordon Alles

Gordon A. Alles
Born Gordon A. Alles
November 26, 1901
Died January 21, 1963 (1963-01-22) (aged 61)
Citizenship American
Education California Institute of Technology
Occupation Chemist, Pharmacologist
Known for Discovering the physiological effects of amphetamine

Gordon A. Alles (November 26, 1901 – January 21, 1963), was an American chemist and pharmacologist who did much research on the isolation and properties of insulin for the treatment of diabetics. He is also credited with discovering and publishing the psychological effects of amphetamine, and for methylenedioxyamphetamine (MDA).[1] He is the first person to have prepared amphetamine sulfate, although not the amphetamine molecule. Alles first reported the physiological properties amphetamine as a synthetic analog of ephedrine, and therefore received credit for this discovery.[2] He enjoyed large royalties from Smith, Kline & French (SKF) because he sold his patent rights for amphetamine to the company and it enjoyed large sales. Several popular products sold by SKF contained amphetamine including Benzedrine pills and inhalers, Dexedrine pills, and Dexamyl tablets. Counterfeit drugs appeared, trying to violate Alles' 'weak' patent, e.g., "Profetamine".[1]


Alles received his BS (1922), MS (1924), and PhD (1926) degrees from California Institute of Technology (Caltech). Since 1931 he had been a lecturer in pharmacology at the University of California Medical School in San Francisco, and since 1951 he had been Professor in Residence of pharmacology at UCLA. From 1934 to 1951 he was a consultant for the SKF laboratories.[3] He was owner of the Alles Chemical Research Laboratories in Pasadena, and had been a Caltech research associate since 1939. In 1958 he gave Caltech a gift of $350,000 which financed, in large part, the five-story Gordon A. Alles Laboratory for Molecular Biology.[2][4]

Alles was primarily interested in natural and synthetic drug chemicals and the relationship between their molecular structures and their biological actions.[5] In 1928 he discovered the physiological properties of benzedrine (amphetamine) and he contributed to its development as a drug. This drug and dextroamphetamine, which was developed from the discovery, have had worldwide medical use as general brain stimulants.[6]

Alles had also spent time in Tahiti, where he was investigating the possibilities of developing tranquilizers from alkaloids in a native drink called kava.[2]

Quote from On Speed.[1]

Gordon Alles never lived to see the downfall of his invention in both medical doctrine and popular opinion. Perhaps inspired by the psychic effects he discovered in methylenedioxyamphetamine (MDA, the original ecstasy) in 1930, Alles devoted almost the whole of his career to mind-altering drugs. In the 1930s and early 1940s, while still working closely with SKF, he produced hallucinogens related to amphetamine and mescaline, including MDA, for the firm to test in low doses as diet drugs and antidepressants. Alles also worked with SKF at isolating medically useful drugs from cannabis. Starting in the late 1950s, having become an honorary pharmacology professor at the medical school of the University of California, Los Angeles, he worked on developing hallucinogenic amphetamines such as MDA and even more powerful derivatives, partly funded by the U.S. Army’s chemical warfare program. He investigated hallucinogenic and stimulant chemicals in the Khat plant, starting with a 1955 expedition to Ethiopia to study how it was used in traditional medicine. In January 1963, upon returning from a Tahiti trip to investigate the traditional Kava root as a source of new tranquilizers, Alles died. The cause of death of this biochemist who had begun his career by studying insulin was, ironically, diabetes, a disease Alles never knew he had. Insulin could have saved his life, of course, but no matter how marvelous a drug may be in itself, it is only beneficial when accompanied by the right diagnosis and prescription.


This article is issued from Wikipedia - version of the 5/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.